Matsumoto, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Professor

Career 【 Display / hide

  • 2003.04
    -
    2007.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04
    -
    2014.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04
    -
    2017.03

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04
    -
    Present

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Academic Background 【 Display / hide

  • 1994.04
    -
    1998.03

    Kumamoto University, 薬学部, 薬学科

    日本, University, Graduated

  • 1998.04
    -
    2000.03

    Kumamoto University, 薬学研究科

    日本, Graduate School, Completed, Master's course

  • 2000.04
    -
    2003.03

    Kumamoto University, 薬学研究科

    日本, Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(薬学), Kumamoto University, Coursework, 2003.03

    α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Licenses and Qualifications 【 Display / hide

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>

 

Research Areas 【 Display / hide

  • Medical pharmacy

Research Keywords 【 Display / hide

  • Drug Delivery System

  • 抗菌化学療法

  • 高齢者医療

Research Themes 【 Display / hide

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

    2014.04
    -
    Present

 

Books 【 Display / hide

  • Clinical Practice Guideline for the Management of Invasive Candidiasis by the Japanese Society for Medical Mycology

    Kazuaki Matsumoto, 日本医真菌学会, 2021.08

  • 抗菌化学療法認定薬剤師テキスト改訂版

    松元一明, 日本化学療法学会, 2021.07

    Scope: 抗菌薬の治療薬物モニタリング,  Contact page: 41-50

  • 今日の治療指針2021

    松元一明, 医学書院, 2021.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

  • 今日の治療薬2021

    松元一明, 南江堂, 2021.01

  • 小児感染症治療ハンドブック2020-2021

    松元一明, 診断と治療社, 2020.12

    Scope: 小児科領域でTDMの対象となる薬剤/PK/PD

display all >>

Papers 【 Display / hide

  • Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

    Hanai Y, Takahashi Y, Niwa T, Mayumi T, Hamada Y, Kimura T, Matsumoto K, Fujii S, Takesue Y

    The Journal of antimicrobial chemotherapy  2022.01

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0305-7453

  • Liposomal artificial red blood cell-based carbon monoxide donor is a potent renoprotectant against cisplatin-induced acute kidney injury

    Taguchi K, Suzuki Y, Tsutsuura M, Hiraoka K, Watabe Y, Enoki Y, Otagiri M, Sakai H, Matsumoto K

    Pharmaceutics (Pharmaceutics)  14 ( 1 )  2022.01

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Cisplatin (CDDP) is an essential anti-tumor agent for chemotherapeutic regimens against various types of cancer. However, the progression of nephrotoxicity, which is the main adverse effect of CDDP, leads to discontinuation of CDDP chemotherapy. Therefore, development of a renopro-tectant against CDDP-induced nephrotoxicity is crucial. Here, the potential of a carbon monoxide (CO)-loaded hemoglobin-vesicle (CO-HbV) as a renoprotectant for CDDP-induced nephrotoxicity was evaluated for its renoprotective effects against CDDP-induced nephrotoxicity, inhibitory effects on the anti-tumor activity of CDDP, and anti-tumor activity. In healthy mice, after pretreatment with either saline, HbV, or CO-HbV prior to CDDP administration, only the CO-HbV pretreatment group ameliorated the progression of CDDP-induced nephrotoxicity by suppressing apoptosis via caspase-3. In experiments using B16-F10 melanoma cells, the half-maximal inhibitory concentration of CDDP decreased with co-incubation with CO-HbV, owing to the anti-tumor activity of CO. CO-HbV pretreatment had no impact on the anti-tumor activity of CDDP in B16-F10 melanoma cell-bearing mice, which was consistent with the results of the cell experiment. Furthermore, CO-HbV pretreatment improved body growth and survival rates. In conclusion, CO-HbV pretreatment is a potent renoprotectant for CDDP-induced nephrotoxicity, allowing treatment with CDDP to be conducted without failure of cancer treatment.

  • Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: a systematic review and meta-analysis.

    Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Tanikawa K, Matsumoto K

    British journal of clinical pharmacology (British Journal of Clinical Pharmacology)   2021.12

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0306-5251

     View Summary

    Aims: The present systematic review and meta-analysis evaluated the incidence of elevated creatine phosphokinase (CPK) levels between daptomycin alone and concomitant daptomycin and statin use. Methods: We searched the PubMed, Web of Sciences, Cochrane Library and ClinicalTrials.gov databases. We analysed the incidence of elevated CPK between daptomycin alone and concomitant daptomycin and statins among studies defining CPK elevation as levels ≥ the upper limit of normal (ULN) or ≥5× ULN. We also analysed the incidence of rhabdomyolysis between the groups. We then calculated the odds ratios (ORs) and 95% confidence intervals (CIs) based on the included studies. Results: Comparing CPK elevation defined as CPK levels ≥ULN, a significantly higher incidence of CPK elevation was observed with concomitant daptomycin and statin use than with daptomycin alone (OR = 2.55, 95% CI 1.78–3.64, P <.00001, I2 = 0%). Likewise, when CPK elevation was defined as CPK levels ≥5× ULN, a significantly higher incidence of CPK elevation was detected with concomitant daptomycin and statin use than with daptomycin alone (OR = 1.89, 95% CI 1.06–3.35, P =.03, I2 = 48%). The incidence of rhabdomyolysis was significantly higher following concomitant daptomycin and statin use than with daptomycin alone (OR = 11.60, 95% CI 1.81–74.37, P =.01, I2 = 0%). Conclusion: The combined use of daptomycin and statins were significant risk factors for the incidence of CPK elevation defined as levels ≥ULN or ≥5× ULN and rhabdomyolysis.

  • Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A.

    Watabe Y, Taguchi K, Sakai H, Enoki Y, Maruyama T, Otagiri M, Kohno M, Matsumoto K

    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (European Journal of Pharmaceutics and Biopharmaceutics)  170   43 - 51 2021.12

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0939-6411

     View Summary

    Carbon monoxide (CO) is expected to attenuate the progression of obliterative bronchiolitis (OB), which is a serious complication after lung transplantation. However, issues in terms of feasible exogenous CO supply, such as continuousness and safety, remain unsolved. Here, we applied nano red blood cells, namely hemoglobin vesicles (Hb-V), as a CO cargo based on the biomimetic concept and investigated the therapeutic potential of CO-loaded Hb-V on OB in orthotopic tracheal transplant model mice. The CO-loaded Hb-V was comprised of negatively charged liposomes encapsulating carbonylhemoglobin with a size of ca. 220 nm. The results of histological evaluation showed that allograft luminal occlusion and fibrosis were significantly ameliorated by treatment with CO-loaded Hb-V compared to treatment with saline, cyclosporine, and Hb-V. The therapeutic effects of CO-loaded Hb-V on OB were due to the suppression of M1 macrophage activation in tracheal allografts, resulting from decreased IL-17A production. Furthermore, the expression of TNF-α and TGF-β in tracheal allografts was decreased by CO-loaded Hb-V treatment but not saline and Hb-V treatment, indicating that CO liberated from CO-loaded Hb-V inhibits epithelial-mesenchymal transition. These findings suggest that CO-loaded Hb-V exerts strong therapeutic efficacy against OB via the regulation of macrophage activation by IL-17A and TGF-β-driven epithelial-mesenchymal transition.

  • Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability.

    Samura M, Hirose N, Kurata T, Takada K, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Higashita R, Kunika N, Tanikawa K, Matsumoto K

    Open forum infectious diseases 8 ( 12 ) ofab568 2021.12

    Research paper (scientific journal), Joint Work, Accepted

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • メトヘモグロビン内包リポソームの新規アジド中毒解毒剤としての有効性評価.

    羽生聡美, 鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 31 - 31 2021.09

    ISSN  1341-1594

  • 一酸化炭素結合型ヘモグロビン小胞体の急性呼吸窮迫症候群に対する有用性評価.

    渡部佑樹, 田口和明, 榎木裕紀, 酒井宏水, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 28 - 28 2021.09

    ISSN  1341-1594

  • メトヘモグロビン内包リポソームの長期安定性評価.

    鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 29 - 29 2021.09

    ISSN  1341-1594

  • 【難しい数式も、TDMもわからない!「ニガテさん」のための薬物動態】(第4章)患者背景によるADMEの変化に注目できる! 高齢者の薬物動態

    榎木 裕紀, 松元 一明

    調剤と情報 ((株)じほう)  27 ( 10 ) 1754 - 1761 2021.07

    Other article, Joint Work,  ISSN  1341-5212

  • 【肺炎をめぐるトピックス:基礎から臨床まで】バンコマイシンをめぐるPK/PD理論の新展開.

    松元 一明

    呼吸器内科 ((有)科学評論社)  39 ( 6 ) 544 - 548 2021.06

    Introduction and explanation (commerce magazine), Single Work,  ISSN  1884-2887

display all >>

Presentations 【 Display / hide

  • メトヘモグロビン内包リポソームの新規アジド中毒解毒剤としての有効性評価.

    羽生聡美, 鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (東京都) , 2021.10, Oral Presentation(general)

  • メトヘモグロビン内包リポソームの長期安定性評価.

    鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (東京都) , 2021.10, Oral Presentation(general)

  • 一酸化炭素結合型ヘモグロビン小胞体の急性呼吸窮迫症候群に対する有用性評価.

    渡部佑樹, 田口和明, 榎木裕紀, 酒井宏水, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (東京都) , 2021.10, Oral Presentation(general)

  • 健康セミナー参加者を対象としたセルフメディケーション税制に関する実態調査.

    田口和明, 榎木裕紀, 有賀聡美, 榊原幹夫, 堀里子, 山浦克典, 松元一明

    第31回日本医療薬学会年会 (熊本県) , 2021.10, Poster (general)

  • 廃用性筋萎縮による敗血症病態増悪における骨格筋由来エクソソームの関与.

    長邑花, 榎木裕紀, 田口和明, 松元一明

    第31回日本医療薬学会年会 (熊本県) , 2021.10, Oral Presentation(general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

    2021.09
    -
    2023.08

    大日本住友製薬株式会社, 松元 一明, Commissioned research, Principal Investigator

  • 肺Mycobacterium abscessus complex症に対するクロファジミンの有効性及び安全性を検討する医師主導治験実施のためのプロトコール作成研究

    2021.08
    -
    2022.03

    国立研究開発法人日本医療研究開発機構(AMED), 革新的医療シーズ実用化研究事業, 南宮 湖, 松元 一明, Joint research, Co-investigator

  • MRSA骨感染症の克服を目指したテジゾリド最適化投与法の構築

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 渡部 欣忍, 松元 一明, Grant-in-Aid for Scientific Research (C), Co-investigator

  • Hollow-Fiber Infection Modelを応用した新型コロナウイルス感染症(COVID-19)対する治療薬の開発促進に向けた評価法・検証法の構築に資する基盤研究

    2021.01
    -
    2022.03

    国立研究開発法人日本医療研究開発機構(AMED), 新興・再興感染症に対する革新的医薬品等開発推進研究事業, 舘田 一博, 松元 一明, Joint research, Co-investigator

  • OP0595の臨床有効性評価

    2019.07
    -
    2021.12

    Meiji Seikaファルマ株式会社, 松元 一明, Commissioned research, Principal Investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Application No.: 特願2020-144044  2020.08 

    Patent, Joint, National application

Awards 【 Display / hide

  • 第31回日本医療薬学会年会 Young Investigator’s Award

    長邑花、榎木裕紀、田口和明、松元一明, 2021.10, 廃用性筋萎縮による敗血症病態増悪における骨格筋由来エクソソームの関与

    Country: 日本

  • MRSAフォーラム2020 一般演題優秀賞

    田代渉、北廣夕貴、森山大夢、濱村有那、高畑勇、川邊理奈、榎木裕紀、田口和明、松元一明, 2021.07, MRSA菌血症に対するダプトマイシンとバンコマイシンの有効性及び安全性の評価:システマティックレビュー&メタ解析

    Country: 日本

  • MRSAフォーラム2020 一般演題優秀賞

    小島菜奈、筒浦萌子、森山大夢、水上雄貴、田代渉、長邑花、榎木裕紀、田口和明、竹末芳生、松元一明, 2021.07, バンコマイシンの有効性、安全性に関係するAUCとトラフ目標値、及びAUC ガイドとトラフガイドの比較に関するsystematic review、メタ解析

    Country: 日本

  • 2020 Top Reviewer Award for Biological and Pharmaceutical Bulletin (BPB)

    松元一明, 2021.05

    Country: 日本

  • 日本薬学会第141年会 口頭発表の部 学生優秀発表賞

    永井智也、榎木裕紀、中村秀明、田口和明、松元一明, 2021.03, 慢性腎臓病誘発サルコペニアに対するapelinの有用性評価

    Country: 日本

display all >>

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2021

  • SEMINAR (PHARMACODYNAMICS)

    2021

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2021

  • RESEARCH FOR BACHELOR'S THESIS 1

    2021

  • PRIOR LEARNING FOR CLINICAL PRACTICE 4

    2021

display all >>

 

Social Activities 【 Display / hide

Memberships in Academic Societies 【 Display / hide

  • 日本医真菌学会, 

    2019.02
    -
    Present
  • 日本DDS学会, 

    2018.05
    -
    Present
  • 日本臨床微生物学会, 

    2018.03
    -
    Present
  • 日本老年薬学会 理事・評議員, 

    2016.04
    -
    Present
  • 日本薬剤学会, 

    2015.12
    -
    Present

display all >>